N@N

Exelixis Announces April 7th Webcast of Presentation at the Leerink Swann Cancer Roundtable Conference

_{//health-fitness.news-articles.net/content/2011/ .. -leerink-swann-cancer-roundtable-conference.html}
^{Published in Health and Fitness on Tuesday, April 5th 2011 at 10:30 GMT by Market Wire}  

SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (Nasdaq:EXEL) announced that Gisela Schwab, M.D., the companya™s executive vice president and chief medical officer, will present at the Leerink Swann Cancer Roundtable Conference at 1:55 p.m. EDT / 10:55 a.m. PDT on Thursday, April 7, 2011, in New York. During the presentation, Dr. Schwab will review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer (CRPC), discuss the pivotal trial plans and regulatory strategy for the compound in CRPC and provide a general business update.

The presentation will be webcast and may be accessed in the Event Calendar under Investors at [ www.exelixis.com ].

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the companya™s web site at [ www.exelixis.com ].